In this respect, although TP53 mutations in naïve B-CLL were usually considered a rare (<5%) event [16-17], a recent study performed using the next generation sequencing technology demonstrated that very small TP53 mutated subclones are present in 9% (28/309) of newly diagnosed B-CLL patients [18], a percentage significantly higher than previously reported by the Sanger technology. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.